American entrepreneur Bryan Johnson has publicly expressed doubts about the effectiveness of his costly personal longevity regimen following a recent diagnosis of a rare autoimmune disorder affecting his stomach lining. Johnson, known for investing approximately SR37.5 million ($10 million) over five years on efforts to slow biological aging, has acknowledged the limitations of such interventions despite reports that he achieved a biological age of 37 while chronologically 48.

Johnson’s approach to longevity, which includes his company Blueprint Bryan Johnson, continues to thrive commercially despite medical setbacks. The company, valued at around SR225 million, markets a range of related products, including a specialized olive oil retailing for SR131 per bottle, which reportedly generates annual revenues exceeding SR93 million. In early 2026, Blueprint launched an exclusive program priced at SR3.75 million annually, modeled on Johnson’s regimen, which attracted 1,500 participants within hours.

Interest in longevity and biohacking is growing in Saudi Arabia, particularly among younger demographics. A 2025 Saudi study published in the journal Healthcare found that more than half of those engaged with longevity research in the Kingdom are aged between 18 and 25. This trend aligns with a global market estimated at SR108.78 billion in 2024, driven by commercial ventures that cater to consumer concerns about aging and mortality.

However, experts caution that high expenditures on longevity may produce only modest increases in lifespan, often ranging from zero to four years, when compared to the benefits of healthy lifestyle practices. Research published in Nature Aging by S. Jay Olshansky highlights biological constraints on human lifespan that may not be surmountable through financial means alone. Historical and contemporary examples, such as the late American billionaire David Rockefeller’s pursuit of life extension before his death at 101, and the longevity observed among populations in established Blue Zones like Okinawa, suggest that balanced diets and regular exercise remain crucial factors in healthy aging.

Saudi Arabia maintains strict regulatory standards aimed at safeguarding consumers from unverified longevity claims. Authorities emphasize the importance of directing investment into scientifically grounded research, particularly in managing chronic age-related diseases through early intervention. The Hevolution Foundation, backed by the Saudi government’s annual budget of SR3.75 billion, exemplifies this approach by funding healthy-lifespan research with a focus on clinically proven treatments.

While consumer-driven biohacking and luxury longevity programs attract significant attention and capital, experts argue that state-supported geroscience and integration into the national healthcare system offer a more promising path toward extending healthspan. Aligning initiatives with Saudi Vision 2030’s public health goals could improve access to safe, evidence-based therapies and potentially reduce long-term healthcare costs by prioritizing prevention and disease management over unproven trends.